<DOC>
	<DOC>NCT02034877</DOC>
	<brief_summary>This study is to describe the safety and immunogenicity of 13vPnC in Indian adults 50 to 65 years of age and in Indian children 6 to 17 years of age.</brief_summary>
	<brief_title>13-valent Pneumococcal Conjugate Vaccine Study in Adults and Children in India</brief_title>
	<detailed_description />
	<mesh_term>Pneumonia</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
	<criteria>Indian adults subjects between 50 and 65 years of age and indian children between 6 and 17years of age, determined by clinical judgment to be eligible for 13vPnC vaccination. Any contraindication to 13vPnC vaccination, vaccination with any pneumococcal vaccine within the last year</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>13-valent pneunococcal conjugate vaccine</keyword>
	<keyword>pneumococcal disease prevention; safety and immunogenicity study</keyword>
</DOC>